Valiant Laboratories credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

44.9	44.9	121	76.1
11.8	11.8	45.2	−67.8
0.14×	0.14×	0.52×	0.32×
0.04×	0.04×	0.19×	−0.29×
7.03×	7.03×	−25.90×	−9.05×
0.35×	1.85×	−9.66×	8.06×
0.18×	0.18×	−38.63×	−133.33×
12.6%	12.6%	34.1%	24.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VALIANTLAB₹128.33

Valiant Laboratories Limited

· Pharma & Health

₹ CrorePeersALBERTDAVD HALEOSLABS ZIMLAB MEDICO MEDICAMEQ ANUHPHR AHCL WANBURYMcap ₹697 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	76.1	121.2	44.9	44.9
Net Debt	-67.8	45.2	11.8	11.8
Total Debt/Equity	0.32	0.52	0.14	0.14
Net Debt/Equity	-0.29	0.19	0.04	0.04
Total Debt/EBITDA	-9.05	-25.90	7.03	7.03
Net Debt/EBITDA	8.06	-9.66	1.85	0.35
Interest Coverage (EBIT/Interest)	-133.33	-38.63	0.18	0.18
Total Debt/Total Capital %	24.30	34.09	12.63	12.63

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.